Placebo Narlaprevir — Competitive Intelligence Brief

Placebo Narlaprevir (Placebo Narlaprevir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: protease inhibitor. Area: Infectious Diseases.

phase 3 protease inhibitor NS3/4A protease Infectious Diseases Small molecule

Target snapshot

Placebo Narlaprevir (Placebo Narlaprevir) — R-Pharm. Narlaprevir is a protease inhibitor used to treat hepatitis C virus (HCV) infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo Narlaprevir TARGET	Placebo Narlaprevir	R-Pharm	phase 3	protease inhibitor	NS3/4A protease
Simeprevir + Sofosbuvir	Simeprevir + Sofosbuvir	Federal University of São Paulo	marketed	Antiviral combination (protease inhibitor + nucleotide polymerase inhibitor)	HCV NS3/4A protease and HCV NS5B RNA-dependent RNA polymerase
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase
sofosbubir/velpatasvir/voxilaprevir	sofosbubir/velpatasvir/voxilaprevir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase, NS5A protein, NS3/4A protease
EXVIERA	EXVIERA	HaEmek Medical Center, Israel	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS5B, NS3/4A protease
Ombitasvir-Paritaprevir-Ritonavir	Ombitasvir-Paritaprevir-Ritonavir	University of Modena and Reggio Emilia	marketed	HCV protease inhibitor and NS5A inhibitor combination	HCV NS3/4A protease, HCV NS5A protein
Grazaoprevir/Elbasavir/RBV	Grazaoprevir/Elbasavir/RBV	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog	HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (protease inhibitor class)

1. Tibotec Pharmaceuticals, Ireland · 3 drugs in this class
2. AbbVie · 1 drug in this class
3. AbbVie (prior sponsor, Abbott) · 1 drug in this class
4. R-Pharm · 1 drug in this class
5. Tanabe Pharma Corporation · 1 drug in this class